Data on drug transfer into human breast milk are sparse. This study aimed to quantify concentrations of cetirizine and levocetirizine in breast milk and to estimate drug exposure to infants. Breastfeeding women at least 8 weeks postpartum and using cetirizine or its pure (R)‐enantiomer levocetirizine were eligible to participate. Breast milk samples were collected at six predefined times during a dose interval (0, 2, 4, 8, 12 and 24 h after drug intake) at steady state. Infant drug exposure was estimated by calculating the absolute infant dose (AID) and the weight‐adjusted relative infant dose (RID). In total, 32 women were eligible for final inclusion, 31 women using cetirizine and one woman using levocetirizine. Means of the individual maximum and average cetirizine milk concentrations were 41.0 and 16.8 μg/L, respectively. Maximum concentrations occurred on average 2.4 h after intake, and the mean half‐life in milk was 7.0 h. Estimated AID and RID for cetirizine in a day were 2.5 μg/kg and 1.9%, respectively. The corresponding values for levocetirizine were 1.1 μg/kg and 1.9%. No severe adverse events were reported. Our findings demonstrate that the transfer of cetirizine and levocetirizine into breast milk is low and compatible with breastfeeding.
The blood–brain barrier (BBB) poses major challenges to drug delivery to the CNS. SFTI-1 and kalata B1 are cyclic cell-penetrating peptides (cCPPs) with high potential to be used as scaffolds for drug delivery. We here studied their transport across the BBB and distribution within the brain to gauge the potential of these two cCPPs as scaffolds for CNS drugs. In a rat model, SFTI-1 exhibited, for a peptide, high extent of BBB transport with a partitioning of unbound SFTI-1 across the BBB, Kp,uu,brain, of 13%, while only 0.5% of kalata B1 equilibrated across the BBB. By contrast, kalata B1, but not SFTI-1, readily entered neural cells. SFTI-1, but not kalata B1, could be a potential CNS delivery scaffold for drugs directed to extracellular targets. These findings indicate that differences between the BBB transport and cellular uptake abilities of CPPs are crucial in the development of peptide scaffolds.
4 November 2024 in Basic & Clinical Pharmacology & Toxicology
Cetirizine is an antihistamine commonly used to treat allergic rhinitis and other allergic conditions. Cetirizine is often prescribed to breastfeeding mothers although there is limited information on infant exposure via breast milk. The aim of this study was to develop a popPK model based on data from a lactation study to predict cetirizine breast milk concentrations and estimate the relative infant dose (RID) in a breastfed infant. A popPK model was developed in NONMEM on data from a human lactation study including 35 women using cetirizine or levocetirizine while breastfeeding. Serial samples of breast milk were collected (n = 205) and the cetirizine concentrations quantified using a validated LC–MS/MS method. A one‐compartment model of cetirizine in breast milk was developed and employed to calculate the relative infant dose (RID). Covariates related to the maternal characteristics and breastfeeding patterns were evaluated in the model; only milk sampling pumping duration was found to be a significant covariate, with an increasing pumping duration leading to an increased apparent milk volume of distribution (Vm). The mean RID was 1.99% with the highest RID being 3.36% at Cmax. PopPK modelling could be used to estimate infant exposure to cetirizine via breast milk. The low predicted exposure in infants supports that cetirizine is compatible with breastfeeding.
Aims: The primary aim is to determine the concentration of metformin in the plasma of breastfed infants to lactating women being treated for type 2 diabetes. The secondary aim is to determine the concentration of metformin in breast milk and maternal plasma and the milk-to-plasma ratio of the mothers and to calculate the average daily infant dose (ADID) and relative infant dose (RID). Methods: The study has a low intervention clinical trial design in the sense that breast milk and blood will be collected merely to study excretion of metformin into breastmilk and transferal to her child. Participation in the study will not decide or in any other way interfere with patients’ treatment as prescribed by their physician. Only patients that already have been assigned treatment with metformin by their physician will be approached and asked for participation. All procedures for blood collection will follow established clinical routines at the clinical sites. The sampling will take place ≈ 6-8 weeks postpartum. The study has been approved as a low-intervention clinical trial by the Swedish Medical Product Agency (Publicly available in CTIS (EU CT no. 2022-501693-19-00 and registered in EUPAS 105190) which includes an approval by the Swedish Ethical Review Authority. The date for the ethics approval is 17 February 2023 Results: Up to date (24 February) 18 women and infants have been recruited and sampled. Recruitment is ongoing. Conclusions: An evaluation of pharmacokinetic results as well as clinical experiences related to recruitment and sampling will be systematically conducted upon completion of the study, which is estimated to conclude by the end of 2025. Preliminary experiences suggest that the primary challenge for a study of this nature is recruiting a sufficient number of participants. Highlights: With as few as 5% of available medications being adequately monitored, tested and labelled with safety information for use in breastfeeding women there is a great need to monitor and evaluate the potential risk of transfer of medicines to the infant. We demonstrate here how a low-intervention clinical trial may be designed in order to provide evidence of transfer.